Tianlong launched a campaign to care for SMA children

XI’AN China, July 14, 2022 /PRNewswire/ — Tianlong has launched a campaign together with the Spinal muscular atrophy (SMA) care center in China (a non-profit organization for SMA), and The Second Affiliated Hospital of Xi’an Jiaotong University to care for children with SMA in May 2022.

Spinal muscular atrophy (SMA) is an inherited disease that affects nerves and muscles, causing muscles to become increasingly weak. It mostly affects infants and children but can also develop in adults, ranking as the first fatal genetic disease of infants.

Tianlong always bears social responsibility and strives for making more people know about the disease and helping with early detection. We want to make the world of SMA children full of love with deeds. During the campaign, we invited many families in Xi’an, China to join us to accompany SMA children one day. We have also invited a professor to give a lecture on SMA treatment and help answer concerns from parents.

As a leading molecular diagnosis products manufacturer in China, Tianlong has PCR reagents covering 200 kinds of disease detection, including SMA detection. Based on the PCR melting curve method, Tianlong’s Human Survival Motor Neuron 1 (SMN1) Gene Detection Kit is suitable for the auxiliary diagnosis of SMN1 patients and screening of SMN1 gene carriers. Besides PCR reagents, Tianlong can provide an integrated PCR lab solution from the nucleic acid extractor, and PCR systems to compatible reagents. We have helped over 80 countries in building up healthcare systems in the COVID-19 phase. Our Nucleic acid extractors and PCR machines have been a star in the war against COVID-19.

Every child is a gift to parents. They need to be nurtured with full love. Early detection can help with early diagnosis and treatment. We hope more people know about the rare disease and more SMA children and their families can be seen. We will bring technology to life and provide more solutions to better care for people globally.

Explore Tianlong : https://www.tlgenetech.cn/

Follow us on:

LinkedIn: https://www.linkedin.com/company/tianlongbiotech

Facebook:https://www.facebook.com/TianlongBiotech/

Twitter:https://twitter.com/TianlongBiotech

Contact us:

inquiry@medtl.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/tianlong-launched-a-campaign-to-care-for-sma-children-301586481.html

SOURCE Xi’an TianLong Science and Technology Co., Ltd

Staff

Recent Posts

CannaPharmaRX Provides Corporate Update and Outlines Growth Strategy for 2026

CALGARY, AB / ACCESS Newswire / January 12, 2026 / CannaPharmaRX, Inc. (OTC PINK:CPMD), an…

6 hours ago

TempraMed Closes C$2.5 Million Fully Subscribed Private Placement

Vancouver, British Columbia--(Newsfile Corp. - January 12, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE:…

9 hours ago

TruuCONNECT NJ Statewide Digital Hub Empowers Users to Find Verified, Local Community Resources and Support – Anonymously and in Real Time

MOUNT LAUREL, N.J., Jan. 12, 2026 /PRNewswire/ -- Born out of a partnership between the…

9 hours ago

Nuvo Unveils Large-Scale AI-Ready Pregnancy Dataset Built on Real-World Maternal and Fetal Physiology

Unique longitudinal dataset combining native fetal and maternal ECG with phonocardiography supports deeper insights into…

9 hours ago

Alamar Biosciences Announces Launch of NULISAqpcr™ AD 5-plex Assay, Advancing Blood Based Biomarker Detection in Alzheimer’s Disease Research

FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision…

9 hours ago

RxAnte Announces Strategic Growth Investment from Primus Capital

PORTLAND, Maine, Jan. 12, 2026 /PRNewswire/ -- RxAnte, the leading provider of analytics, software, and…

9 hours ago